NCT01430780

Brief Summary

Basic studies has showed that sustained use of nitrates might associated with adverse effects on vascular function mediated by an increase in nitrate-induced oxidative stress. But it remains unclear whether oxidative stress increases with endothelial function impairment in patients with coronary artery disease (CAD) during administration of long-term oral nitrates. The investigators evaluated whether administration of long-term isosorbide mononitrate (ISMN) treatment was associated with oxidative stress increase and endothelial function impairment in patients with CAD.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
68

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2009

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2009

Completed
2.1 years until next milestone

First Submitted

Initial submission to the registry

September 1, 2011

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 8, 2011

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
Last Updated

March 22, 2013

Status Verified

March 1, 2013

Enrollment Period

4.3 years

First QC Date

September 1, 2011

Last Update Submit

March 21, 2013

Conditions

Keywords

Coronary artery diseasenitrateendothelium

Outcome Measures

Primary Outcomes (1)

  • flow-mediated dilation

    Endothelial function evaluated by brachial artery ultrasound imaging during reactive hyperemia.

    one year

Secondary Outcomes (3)

  • serum superoxide dismutase (SOD) level

    one year

  • serum malondialdehyde (MDA) level

    one year

  • serum hypersensitive C-reactive protein (hsCRP) level

    one year

Study Arms (2)

control group

placebo

Drug: control group

nitrate group

Isosorbide Mononitrate orally 20mg twice per day.

Drug: nitrate group

Interventions

Isosorbide Mononitrate orally 20mg twice per day.

nitrate group

placebo

control group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with catheterization confirmed coronary artery disease.

You may qualify if:

  • Individuals were considered eligible for enrollment if they had at least 1 significant de novo stenosis (reduction ≥50% of the lumen diameter) on any coronary vessel at angiography.

You may not qualify if:

  • Patients with liver and renal failure with creatinine\>3 mg/dL were excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Cardiology, First Affiliated Hospital, College of Medicine, Zhejiang University

Hangzhou, Zhejiang, 310003, China

RECRUITING

Related Publications (1)

  • Lai J, Wu B, Sun J, Shang Y, Zhu J. Long-term isosorbide mononitrate treatment impairs endothelial function in patients with coronary artery disease. Coron Artery Dis. 2013 Nov;24(7):566-71. doi: 10.1097/MCA.0000000000000029.

MeSH Terms

Conditions

Coronary Artery Disease

Interventions

Control Groups

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethods

Study Officials

  • Jiangtao Lai, Doctor

    Zhejiang University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jiangtao Lai, Doctor

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

September 1, 2011

First Posted

September 8, 2011

Study Start

August 1, 2009

Primary Completion

December 1, 2013

Study Completion

December 1, 2013

Last Updated

March 22, 2013

Record last verified: 2013-03

Locations